Monte Carlo evaluation of out-of-field dose in 18 MV pelvic radiotherapy using a simplified female MIRD phantom

This study was devoted to determining the unwanted dose due to scattered photons to the out-of-field organs and subsequently estimate the risk of secondary cancers in the patients undergoing pelvic radiotherapy. A typical 18 MV Medical Linear Accelerator (Varian Clinac 2100 C/D) was modeled using MCNPX® code to simulate pelvic radiotherapy with four treatment fields: anterior-posterior, posterior-anterior, right lateral, left lateral. Dose evaluation was performed inside Medical Internal Radiation Dose (MIRD) revised female phantom. The average photon equivalent dose in out-of-field organs is 8.53 mSv Gy−1, ranging from 0.17 to 72.11 mSv Gy−1, respectively, for the organs far from the Planning Treatment Volume (Brain) and those close to the treatment field (Colon). Evidence showed that colon with 4.3049% and thyroid with 0.0020% have the highest and lowest risk of secondary cancer, respectively. Accordingly, this study introduced the colon as an organ with a high risk of secondary cancer which should be paid more attention in the follow-up of patients undergoing pelvic radiotherapy. The authors believe that this simple Monte Carlo (MC) model can be also used in other radiotherapy plans and mathematical phantoms with different ages (from childhood to adults) to estimate the out-of-field dose. The extractable information by this simple MC model can be also employed for providing libraries for user-friendly applications (e.g. ‘.apk’) which in turn increase the public knowledge about fatal cancer risk after radiotherapy and subsequently decrease the concerns in this regard among the public.

[1]  I. Abedi,et al.  Investigating the out-of-field doses and estimating the risk of secondary thyroid cancer in high-grade gliomas radiation therapy with modulated intensity and 3D-conformal: a phantom study , 2021, International Journal of Radiation Research.

[2]  P. Tangboonduangjit,et al.  Secondary cancer risk from modern external-beam radiotherapy of prostate cancer patients: Impact of fractionation and dose distribution , 2021, Journal of radiation research.

[3]  R. Khabaz Phantom dosimetry and cancer risks estimation undergoing 6 MV photon beam by an Elekta SL-25 linac. , 2020, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[4]  B. Sánchez-Nieto,et al.  Study of out‐of‐field dose in photon radiotherapy: A commercial treatment planning system versus measurements and Monte Carlo simulations , 2020, Medical physics.

[5]  A. H. Karimi,et al.  Grid therapy vs. conventional radiotherapy - 18 MV treatments: Photoneutron contamination along the maze of a linac bunker. , 2020, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[6]  Hosein Ghiasi,et al.  Monte Carlo study on the secondary cancer risk estimations for patients undergoing prostate radiotherapy: A humanoid phantom study. , 2020, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[7]  M. Najafi,et al.  Different Methods of Measuring Neutron Dose/Fluence Generated During Radiation Therapy with Megavoltage Beams , 2020, Health physics.

[8]  H. Brkić,et al.  Essential considerations for accurate evaluation of photoneutron contamination in Radiotherapy. , 2019, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[9]  A. H. Karimi,et al.  Photoneutron Dose Estimation in GRID Therapy Using an Anthropomorphic Phantom: A Monte Carlo Study , 2018, Journal of medical signals and sensors.

[10]  M. Benam,et al.  Estimation of photoneutron dosimetric characteristics in tissues/organs using an improved simple model of linac head. , 2018, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[11]  Ryan L. Smith,et al.  Constituent components of out-of-field scatter dose for 18-MV intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy: a comparison with 6-MV and implications for carcinogenesis. , 2014, International journal of radiation oncology, biology, physics.

[12]  A. Lallena,et al.  Neutron dose equivalent and neutron spectra in tissue for clinical linacs operating at 15, 18 and 20 MV. , 2011, Radiation protection dosimetry.

[13]  Wesley E Bolch,et al.  REVISIONS TO THE ORNL SERIES OF ADULT AND PEDIATRIC COMPUTATIONAL PHANTOMS FOR USE WITH THE MIRD SCHEMA , 2006, Health physics.

[14]  Gary D Fullerton,et al.  Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV, and 18 MV beam energies. , 2006, Medical physics.

[15]  David S Followill,et al.  Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. , 2005, International journal of radiation oncology, biology, physics.

[16]  J. Neglia,et al.  Hypersensitivity and idiosyncratic reactions to oxaliplatin , 2004, Cancer.

[17]  D. Brenner,et al.  Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery , 2000, Cancer.

[18]  D. Schultz,et al.  Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Kase,et al.  Higher energy: is it necessary, is it worth the cost for radiation oncology? , 1992, Medical physics.

[20]  R. Taylor,et al.  Dose levels outside radiotherapy beams. , 1983, The British journal of radiology.

[21]  J. Purdy,et al.  Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications , 1984, Cancer.

[22]  K. Kase,et al.  Measurements of dose from secondary radiation outside a treatment field. , 1983, International journal of radiation oncology, biology, physics.